01—Abstract
Summary
Summary of the 10-K filed February 25, 2005. Cited figures are marked; the original filing is the authoritative source.
Mettler-Toledo International Inc. reported net sales of $1,404.5 milliona for 2004, up from $1,304.4 million in 2003 and $1,213.7 million in 2002, with net sales growing 8% in U.S. dollars in 2004 (5% from currency effects).
Net earnings were $108.0 millionb, or $2.37 diluted EPS, compared with $95.8 million ($2.11) in 2003. Adjusted Operating Income rose to $179.4 million, or 12.8% of net sales, from $161.9 million (12.4%) in 2003. The company describes itself as the world's largest manufacturer of weighing instruments and the world's largest manufacturer and marketer of metal detection and other end-of-line inspection systems, with sales of 43% from Europe, 40% from North and South America and 17% from Asia and other countries.
Balance sheet and cash flow strengthened during 2004. Cash provided by operating activities was $166.0 millionc, versus $117.2 million in 2003. Total debt net of cash was $136.0 million at year-end, with cash of $67.2 million.
The company repurchased 2,208,500 shares for $103.8 milliond at an average price of $46.97 under a program authorized for up to $100 million through 2005 plus an additional $200 million through 2006. The company has historically not paid dividends. The filing also discloses an internal investigation, completed in August 2004, into allegations made by an employee.
The Audit Committee concluded there would be no change to the financial statements, and William Donnelly returned as CFO in August 2004. The company cited $5.0 million of costs related to the investigation and about $3.5 million of external Sarbanes-Oxley compliance fees in 2004. Management identified risks including currency exposure to the Swiss franc, an indefinite-lived $19.9 million license asset subject to litigation, and reliance on pharmaceutical, food and chemical end markets.
02—Key points
Key Highlights
- Net sales of $1,404.5 million in 2004, up from $1,304.4 million in 2003; U.S. dollar growth of 8%, of which 5% reflected currency effects
- Net earnings of $108.0 million ($2.37 diluted EPS) in 2004 versus $95.8 million ($2.11) in 2003
- Adjusted Operating Income of $179.4 million, or 12.8% of net sales, up from $161.9 million (12.4%) in 2003
- Gross margin of 48.6% in 2004 versus 47.4% in 2003, with service revenue of $322.4 million (about 23% of net sales)
- Operating cash flow of $166.0 million, up from $117.2 million; capital expenditures of $27.9 million
- Net debt of $136.0 million at year-end after $67.2 million of cash; $244.6 million available under the $300 million credit facility
- Share repurchases of $103.8 million (2,208,500 shares) in 2004 under a program of up to $100 million through 2005 plus $200 million through 2006
03—Questions
Frequently Asked Questions
What drove revenue growth in 2004?
Net sales grew 8% in U.S. dollars to $1,404.5 million, with 5 percentage points attributed to currency. Local-currency laboratory-related sales rose 4%, and food retailing sales increased 8% excluding currency effects. Asia/Rest of World sales grew 19% in U.S. dollars, and China sales grew 21% in local currency.
Is the company paying dividends?
No. The filing states that Mettler-Toledo has historically not paid dividends on its common stock, and that the Board will evaluate this policy periodically, taking into account results, capital requirements including potential acquisitions, and its share buyback program.
What is the status of the internal investigation?
The Audit Committee's investigation into employee allegations covering accounting, disclosure and non-financial statement matters is complete. The company announced in August 2004 that there would be no change to its financial statements, and the Board made governance and oversight changes, including the return of William Donnelly as CFO. The filing says the company plans additional changes to its financial organization and complaint-reporting methods.
What are the main risks to the business?
The filing highlights currency risk, since a 1% strengthening of the Swiss franc against the euro would reduce annual pre-tax earnings by $0.9 million to $1.1 million; cyclical capital spending in pharmaceutical, food and chemical industries; intense competition; emerging-market exposure; and a $19.9 million indefinite-lived intellectual property license that is in litigation and could result in a non-cash charge of up to $14 million after tax if not upheld.
04—Continue